Pharmaceutical Research

, Volume 33, Issue 8, pp 1862–1872 | Cite as

Synthesis and Characterization of Nanocomposite Microparticles (nCmP) for the Treatment of Cystic Fibrosis-Related Infections

  • Zimeng Wang
  • Samantha A. Meenach
Research Paper



Pulmonary antibiotic delivery is recommended as maintenance therapy for cystic fibrosis (CF) patients who experience chronic infections. However, abnormally thick and sticky mucus present in the respiratory tract of CF patients impairs mucus penetration and limits the efficacy of inhaled antibiotics. To overcome the obstacles of pulmonary antibiotic delivery, we have developed nanocomposite microparticles (nCmP) for the inhalation application of antibiotics in the form of dry powder aerosols.


Azithromycin-loaded and rapamycin-loaded polymeric nanoparticles (NP) were prepared via nanoprecipitation and nCmP were prepared by spray drying and the physicochemical characteristics were evaluated.


The nanoparticles were 200 nm in diameter both before loading into and after redispersion from nCmP. The NP exhibited smooth, spherical morphology and the nCmP were corrugated spheres about 1 μm in diameter. Both drugs were successfully encapsulated into the NP and were released in a sustained manner. The NP were successfully loaded into nCmP with favorable encapsulation efficacy. All materials were stable at manufacturing and storage conditions and nCmP were in an amorphous state after spray drying. nCmP demonstrated desirable aerosol dispersion characteristics, allowing them to deposit into the deep lung regions for effective drug delivery.


The described nCmP have the potential to overcome mucus-limited pulmonary delivery of antibiotics.


cystic fibrosis nanocomposite microparticles pulmonary delivery spray drying 



Acetalated dextran






Deuterated chloroform


Cystic fibrosis


Cystic fibrosis transmembrane conductance regulator


Deuterium oxide


N,N′-dicyclohexyl- carbodiimde


Deuterium chloride


4-(dimethylamino) pyridine


Emitted dose


Encapsulation efficiency


Fine particle dose


Fine particles fraction


Hydroxypropyl methylcellulose


Karl Fischer


Poly(ethylene glycol) methyl ether


Nanocomposite microparticles


Next Generation Impactor






Powder X-ray diffraction




Respirable fraction


2-methoxypropene (2-MOP), triethylamine


poly(ethylene glycol) vitamin E


Acknowledgments And Disclosures

The authors gratefully acknowledge financial support from an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM103430. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors thank RI-INBRE for HPLC access and RIN2 for SEM, DLS, PXRD, and DSC access.

Supplementary material

11095_2016_1921_MOESM1_ESM.docx (160 kb)
ESM 1 (DOCX 159 kb)
11095_2016_1921_MOESM2_ESM.docx (36 kb)
ESM 2 (DOCX 35 kb)


  1. 1.
    Bowenand S-J, Hull J. The basic science of cystic fibrosis. Paediatr Child Health. 2015;25:159–64.CrossRefGoogle Scholar
  2. 2.
    Bradbury NA. Cystic Fibrosis. In: Bradshaw RA, Stahl PD, Gilbert A, editors. Encyclopedia of Cell Biology, 1st ed. Waltham; 2015. p 283–293.Google Scholar
  3. 3.
    Thursfieldand RM, Davies JC. Cystic Fibrosis: therapies targeting specific gene defects. Paediatr Respir Rev. 2012;13:215–9.CrossRefGoogle Scholar
  4. 4.
    Chuchalin A, Amelina E, Bianco F. Tobramycin for inhalation in cystic fibrosis: beyond respiratory improvements. Pulm Pharmacol Ther. 2009;22:526–32.CrossRefPubMedGoogle Scholar
  5. 5.
    Milla CE. Nutrition and lung disease in cystic fibrosis. Clin Chest Med. 2007;28:319–30.CrossRefPubMedGoogle Scholar
  6. 6.
    FibrosisFoundation C. Patient registry 2005 annual report. Maryland: Bethesda; 2005.Google Scholar
  7. 7.
    Heijerman H, Westerman E, Conway S, Touw D. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2009;8:295–315.CrossRefPubMedGoogle Scholar
  8. 8.
    Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect. 2002;17:47–56.CrossRefPubMedGoogle Scholar
  9. 9.
    Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than Do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990;141:914–21.CrossRefPubMedGoogle Scholar
  10. 10.
    Wagner T, Soong G, Sokol S, Saiman L, Prince A. EFfects of azithromycin on clinical isolates of pseudomonas aeruginosa from cystic fibrosis patients. Chest. 2005;128:912–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Southernand KW, Barker PM. Azithromycin for cystic fibrosis. Eur Respir J. 2004;24:834–8.CrossRefGoogle Scholar
  12. 12.
    Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with pseudomonas aeruginosa: A randomized controlled trial. JAMA. 2003;290:1749–56.CrossRefPubMedGoogle Scholar
  13. 13.
    Wilms EB, Touw DJ, Heijerman HGM, van der Ent CK. Azithromycin maintenance therapy in patients with cystic fibrosis: A dose advice based on a review of pharmacokinetics, efficacy, and side effects. Pediatr Pulmonol. 2012;47:658–65.CrossRefPubMedGoogle Scholar
  14. 14.
    Piscitalle SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharmacol. 1992;11:137–52.Google Scholar
  15. 15.
    Zhao M, You Y, Ren Y, Zhang Y, Tang X. Formulation, characteristics and aerosolization performance of azithromycin DPI prepared by spray-drying. Powder Technol. 2008;187:214–21.CrossRefGoogle Scholar
  16. 16.
    Abdulrahman BA, Khweek AA, Akhter A, Caution K, Kotrange S, Abdelaziz DHA, et al. Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis. Autophagy. 2011;7:1359–70.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Chen Y-C, Lo C-L, Lin Y-F, Hsiue G-H. Rapamycin encapsulated in dual-responsive micelles for cancer therapy. Biomaterials. 2013;34:1115–27.CrossRefPubMedGoogle Scholar
  18. 18.
    Broaders KE, Cohen JA, Beaudette TT, Bachelder EM, Frechet JMJ. Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy. Proc Natl Acad Sci U S A. 2009;106:5497–502.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Cook RO, Pannu RK, Kellaway IW. Novel sustained release microspheres for pulmonary drug delivery. J Control Release. 2005;104:79–90.CrossRefPubMedGoogle Scholar
  20. 20.
    Kauffman KJ, Kanthamneni N, Meenach SA, Pierson BC, Bachelder EM, Ainslie KM. Optimization of rapamycin-loaded acetalated dextran microparticles for immunosuppression. Int J Pharm. 2012;422:356–63.CrossRefPubMedGoogle Scholar
  21. 21.
    Broaders KE, Cohen JA, Beaudette TT, Bachelder EM, Fréchet JMJ. Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy. Proc Natl Acad Sci. 2009;106:5497–502.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Bachelder EM, Beaudette TT, Broaders KE, Dashe J, Fréchet JMJ. Acetal-derivatized dextran: an acid-responsive biodegradable material for therapeutic applications. J Am Chem Soc. 2008;130:10494–5.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Sham JOH, Zhang Y, Finlay WH, Roa WH, Löbenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm. 2004;269:457–67.CrossRefPubMedGoogle Scholar
  24. 24.
    Ong HX, Traini D, Ballerin G, Morgan L, Buddle L, Scalia S, et al. Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases. AAPS J. 2014;16:269–80.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Jensen DMK, Cun D, Maltesen MJ, Frokjaer S, Nielsen HM, Foged C. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J Control Release. 2010;142:138–45.CrossRefPubMedGoogle Scholar
  26. 26.
    Littringer EM, Mescher A, Schroettner H, Achelis L, Walzel P, Urbanetz NA. Spray dried mannitol carrier particles with tailored surface properties – The influence of carrier surface roughness and shape. Eur J Pharm Biopharm. 2012;82:194–204.CrossRefPubMedGoogle Scholar
  27. 27.
    Cooney GF, Lum BL, Tomaselli M, Fiel SB. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol. 1994;34:255–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: A critical evaluation. Eur J Pharm Biopharm. 2014;86:23–30.CrossRefPubMedGoogle Scholar
  29. 29.
    Stanojevic S, Waters V, Mathew JL, Taylor L, Ratjen F. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis. J Cyst Fibros. 2014;13:172–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. PHarmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002;122:219–26.CrossRefPubMedGoogle Scholar
  31. 31.
    Dolovichand MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011;377:1032–45.CrossRefGoogle Scholar
  32. 32.
    Ibrahim BM, Tsifansky MD, Yang Y, Yeo Y. Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease. Expert Opin Drug Deliv. 2011;8:451–66.CrossRefPubMedGoogle Scholar
  33. 33.
    Kuzmovand A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release. 2015;219:500–18.CrossRefGoogle Scholar
  34. 34.
    Daniels T, Mills N, Whitaker P. Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database Syst Rev. 2013. doi: 10.1002/14651858.CD007639.pub2.
  35. 35.
    Tang BC, Dawson M, Lai SK, Wang Y-Y, Suk JS, Yang M, et al. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci. 2009;106(46):19268–73. doi: 10.1073/pnas.0905998106.
  36. 36.
    Stegemann S, Kopp S, Borchard G, Shah VP, Senel S, Dubey R, et al. Developing and advancing dry powder inhalation towards enhanced therapeutics. Eur J Pharm Sci. 2013;48:181–94.CrossRefPubMedGoogle Scholar
  37. 37.
    Wattsand AB, Williams RO. Nanoparticles for pulmonary delivery. In: Smythand DCH, Hickey JA, editors. Controlled pulmonary drug delivery. New York: Springer; 2011. p. 335–66.CrossRefGoogle Scholar
  38. 38.
    Collnot E-M, Baldes C, Wempe MF, Hyatt J, Navarro L, Edgar KJ, et al. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J Control Release. 2006;111:35–40.CrossRefPubMedGoogle Scholar
  39. 39.
    Meenach SA, Anderson KW, Zach Hilt J, McGarry RC, Mansour HM. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur J Pharm Sci. 2013;49:699–711.CrossRefPubMedGoogle Scholar
  40. 40.
    F. W. The ARLA Respiratory deposition calculator 2008.Google Scholar
  41. 41.
    Mert O, Lai SK, Ensign L, Yang M, Wang Y-Y, Wood J, et al. A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles. J Control Release. 2012;157:455–60.CrossRefPubMedGoogle Scholar
  42. 42.
    Bootz A, Vogel V, Schubert D, Kreuter J. Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm. 2004;57:369–75.CrossRefPubMedGoogle Scholar
  43. 43.
    Meenach SA, Kim YJ, Kauffman KJ, Kanthamneni N, Bachelder EM, Ainslie KM. Synthesis, optimization, and characterization of camptothecin-loaded acetalated dextran porous microparticles for pulmonary delivery. Mol Pharm. 2012;9:290–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Wu X, Hayes D, Zwischenberger JB, Kuhn RJ, Mansour HM. Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation. Drug Des Devel Ther. 2013;7:59–72.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Meenach SA, Vogt FG, Anderson KW, Hilt JZ, McGarry RC, Mansour HM. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int J Nanomedicine. 2013;8:275–93.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Wu X, Zhang W, Hayes D, Mansour HM. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery. Int J Nanomedicine. 2013;8:1269–83.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Liand X, Mansour HM. Physicochemical characterization and water vapor sorption of organic solution advanced spray-dried inhalable trehalose microparticles and nanoparticles for targeted Dry powder pulmonary inhalation delivery. AAPS PharmSciTech. 2011;12:1420–30.CrossRefGoogle Scholar
  48. 48.
    Hickey AJ, Mansour HM, Telko MJ, Xu Z, Smyth HDC, Mulder T, et al. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sci. 2007;96:1282–301.CrossRefPubMedGoogle Scholar
  49. 49.
    Chew NYK, Chan H-K. The Role of particle properties in pharmaceutical powder inhalation formulations. J Aerosol Med. 2002;15:325–30.CrossRefPubMedGoogle Scholar
  50. 50.
    Mohammadi G, Valizadeh H, Barzegar-Jalali M, Lotfipour F, Adibkia K, Milani M, et al. Development of azithromycin–PLGA nanoparticles: physicochemical characterization and antibacterial effect against salmonella typhi. Colloids Surf B: Biointerfaces. 2010;80:34–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Kaialyand W, Nokhodchi A. Dry powder inhalers: physicochemical and aerosolization properties of several size-fractions of a promising alterative carrier, freeze-dried mannitol. Eur J Pharm Sci. 2015;68:56–67.CrossRefGoogle Scholar
  52. 52.
    Zhang Z, Xu L, Chen H, Li X. Rapamycin-loaded poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) nanoparticles: preparation, characterization and potential application in corneal transplantation. J Pharm Pharmacol. 2014;66:557–63.CrossRefPubMedGoogle Scholar
  53. 53.
    Li X, Chang S, Du G, Li Y, Gong J, Yang M, et al. Encapsulation of azithromycin into polymeric microspheres by reduced pressure-solvent evaporation method. Int J Pharm. 2012;433:79–88.CrossRefPubMedGoogle Scholar
  54. 54.
    Ungaro F, De Rosa G, Miro A, Quaglia F, La Rotonda MI. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci. 2006;28:423–32.CrossRefPubMedGoogle Scholar
  55. 55.
    Suarez S, Hickey AJ. Drug properties affecting aerosol behavior. Respir Care. 2000;45:652–66.PubMedGoogle Scholar
  56. 56.
    Hickey AJ, Heidi M. Delivery of Drugs by the Pulmonary Route. In: Florence AT, Siepmann J. editors. Modern Pharmaceutics: Applications and Advances, 5th ed. New York: Informa Healthcare; 2009. p 191–219.Google Scholar
  57. 57.
    Hickey AJ, Mansour HM. Formulation challenges of powders for the delivery of small molecular weight molecules as aerosols. In: Rathbone MJ, Hadgraft J, Roberts MS, Lane ME, editors. Modified-release drug delivery technology, 2nd ed. New York: Informa Healthcare; 2008. p. 573–602.Google Scholar
  58. 58.
    Edwards DA. The macrotransport of aerosol particles in the lung: aerosol deposition phenomena. J Aerosol Sci. 1995;26:293–317.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Chemical EngineeringUniversity of Rhode IslandKingstonUSA
  2. 2.Department of Biomedical and Pharmaceutical SciencesUniversity of Rhode IslandKingstonUSA

Personalised recommendations